Show simple item record

Counterfactual Links to the Proportion of Treatment Effect Explained by a Surrogate Marker

dc.contributor.authorTaylor, Jeremy M. G.en_US
dc.contributor.authorWang, Yueen_US
dc.contributor.authorThiébaut, Rodolpheen_US
dc.date.accessioned2010-04-01T14:53:54Z
dc.date.available2010-04-01T14:53:54Z
dc.date.issued2005-12en_US
dc.identifier.citationTaylor, Jeremy M. G.; Wang, Yue; ThiÉbaut, Rodolphe (2005). "Counterfactual Links to the Proportion of Treatment Effect Explained by a Surrogate Marker." Biometrics 61(4): 1102-1111. <http://hdl.handle.net/2027.42/65353>en_US
dc.identifier.issn0006-341Xen_US
dc.identifier.issn1541-0420en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/65353
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16401284&dopt=citationen_US
dc.description.abstractIn a randomized clinical trial, a statistic that measures the proportion of treatment effect on the primary clinical outcome that is explained by the treatment effect on a surrogate outcome is a useful concept. We investigate whether a statistic proposed to estimate this proportion can be given a causal interpretation as defined by models of counterfactual variables. For the situation of binary surrogate and outcome variables, two counterfactual models are considered, both of which include the concept of the proportion of the treatment effect, which acts through the surrogate. In general, the statistic does not equal either of the two proportions from the counterfactual models, and can be substantially different. Conditions are given for which the statistic does equal the counterfactual model proportions. A randomized clinical trial with potential surrogate endpoints is undertaken in a scientific context; this context will naturally place constraints on the parameters of the counterfactual model. We conducted a simulation experiment to investigate what impact these constraints had on the relationship between the proportion explained (PE) statistic and the counterfactual model proportions. We found that observable constraints had very little impact on the agreement between the statistic and the counterfactual model proportions, whereas unobservable constraints could lead to more agreement.en_US
dc.format.extent178707 bytes
dc.format.extent3110 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishingen_US
dc.rightsThe International Biometric Society, 2005en_US
dc.subject.otherCausal Effectsen_US
dc.subject.otherClinical Trialen_US
dc.subject.otherCounterfactual Modelen_US
dc.subject.otherDirect Effecten_US
dc.subject.otherIndirect Effecten_US
dc.subject.otherSurrogate Markeren_US
dc.titleCounterfactual Links to the Proportion of Treatment Effect Explained by a Surrogate Markeren_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelMathematicsen_US
dc.subject.hlbtoplevelScienceen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Biostatistics, University of Michigan, Ann Arbor, Michigan 48109, U.S.A.en_US
dc.contributor.affiliationotherResearch Laboratory, Merck & Co., West Point, Pennsylvania 19486, U.S.A.en_US
dc.contributor.affiliationotherINSERM E0338 Biostatistics, ISPED, Bordeaux 2 University, Bordeaux 33076, Franceen_US
dc.identifier.pmid16401284en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/65353/1/j.1541-0420.2005.00380.x.pdf
dc.identifier.doi10.1111/j.1541-0420.2005.00380.xen_US
dc.identifier.sourceBiometricsen_US
dc.identifier.citedreferenceAboulker, J., Babiker, A., Flandre, P., Gazzard, B., Loveday, C., Nunn, A. ( 1999 ). An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. AIDS 13, 565 – 573.en_US
dc.identifier.citedreferenceBuyse, M., Molenberghs, G., Burzykowski, T., Renard, D., and Geys, H. ( 2000 ). Validation of surrogate endpoints in meta-analysis of randomized experiments. Biostatistics 1, 49 – 68.en_US
dc.identifier.citedreferenceDaniels, M. and Hughes, M. ( 1997 ). Meta-analysis for the evaluation of potential surrogate markers. Statistics in Medicine 16, 1965 – 1982.en_US
dc.identifier.citedreferenceDelta. ( 1996 ). Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 348, 283 – 291.en_US
dc.identifier.citedreferenceDitlevsen, S., Christensen, U., Lynch, J., Damsgaard, M., and Keiding, N. ( 2005 ). The mediation proportion: A structural equation approach for estimating the proportion of exposure effect on outcome explained by an intermediate variable. Epidemiology 16, 114 – 120.en_US
dc.identifier.citedreferenceFrangakis, C. and Rubin, D. ( 2002 ). Principal stratification in causal inference. Biometrics 58, 21 – 29.en_US
dc.identifier.citedreferenceFreedman, L., Graubard, B., and Schatzkin, A. ( 1992 ). Statistical validation of intermediate endpoints for chronic disease. Statistics in Medicine 11, 167 – 178.en_US
dc.identifier.citedreferenceHughes, M. E. A. ( 2000 ). Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis. HIV Surrogate Marker Collaborative Group. AIDS Research and Human Retroviruses 16, 1123 – 1133.en_US
dc.identifier.citedreferenceLazzarin, A., Clotet, B., Cooper, D., et al.. ( 2003 ). Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. New England Journal of Medicine 348, 2186 – 2195.en_US
dc.identifier.citedreferenceLi, Z., Meredith, M., and Hoseyni, M. ( 2001 ). A method to assess the proportion of treatment effect explained by a surrogate endpoint. Statistics in Medicine 20, 3175 – 3188.en_US
dc.identifier.citedreferencePrentice, R. ( 1989 ). Surrogate endpoints in clinical trials: Definition and operational criteria. Statistics in Medicine 8, 431 – 440.en_US
dc.identifier.citedreferenceRobins, J. and Greenland, S. ( 1992 ). Identifiability and exchangeability of direct and indirect effects. International Journal of Epidemiology 3, 143 – 155.en_US
dc.identifier.citedreferenceTsiatis, A., De Gruttola, V., and Wulfsohn, M. ( 1995 ). Modeling the relationship of survival to longitudinal data measured with error: Applications to survival and CD4 counts in patients with AIDS. Journal of the American Statistical Association 90, 27 – 37.en_US
dc.identifier.citedreferenceWang, Y. and Taylor, J. ( 2002 ). A measure of the proportion of treatment effect explained by a surrogate marker. Biometrics 58, 803 – 812.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.